Chicago, IL, July 08, 2006 --(PR.com
)-- CytoCore, Inc. (OTCBB: MCDG.OB), a biomolecular diagnostics screening company has announced that the firm has signed an agreement with MMI Associates, Inc. for public relations and marketing services. MMI will provide PR, media relations and product marketing support, as well as increase brand recognition regarding CytoCore’s newest products for cervical and uterine cancer screening.
CytoCore’s CEO Dr. David Weissberg said, “I am confident that MMI’s past experience with medical clinical trials and their work on public campaigns in the cervical cancer testing area will make this a beneficial partnership. Since they are a woman owned business, they understand the value and importance of our work. We anticipate MMI’s work for CytoCore will be instrumental in helping to raise awareness about CytoCore’s unique products and solutions for cervical and uterine cancer screening.”
“We are pleased to work with CytoCore,” said Patty Briguglio, president of MMI Associates, Inc. “Our experience working with public awareness campaigns for cervical cancer testing gives us an appreciation for the impact CytoCore’s screening products can have in this critical area of women’s health. Working with CytoCore will enable us inform and educate physicians and their patients of important issues surrounding cervical and uterine cancer screening.”
About MMI Associates, Inc.
MMI Associates, Inc. is a full-service marketing and public relations firm offering a wide range of services to help clients achieve measurable results in brand awareness, name recognition, market penetration and crisis management. Established in 1994 in Phoenix, Arizona, this award-winning firm was named one of the top 10 public relations firms in the state by Arizona Business Magazine and bizAZ Magazine. In North Carolina, the Triangle Business Journal’s Book of Lists for 2004 and 2005 recognized MMI as one of the top public relations firms in the Triangle. The firm has received numerous MarCom Creative Awards, the 2005 Videographer Award and the 2005 Millennium Award. For more information, please call 919-233-6600 or visit the Web site at http://www.mmimarketing.com.
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath™ System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com
Certain statements in this release are forward-looking. These statements are based on CytoCore’s current expectations and involve many risks and uncertainties, such as the company’s inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore’s expectations with respect to the InPath™ System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore’s current expectation depending upon a number of factors affecting the Company’s business. These factors include, among others, risks and uncertainties detailed in the Company’s periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
MMI Associates, Inc.